Oculis Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCS research report →
Range $26 – $45
Price Chart
About the company
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.
- CEO
- Riad Sherif
- IPO
- 2021
- Employees
- 60
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on OCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $487.95M
- P/E
- -5.07
- Fwd P/E
- 11.34
- PEG
- -0.09
- P/S
- 1671.41
- P/B
- 1.98
- EV/EBITDA
- -5.21
- Div Yield
- 0.00%
- Gross Margin
- 35.21%
- Op Margin
- -35874.24%
- Net Margin
- -32780.20%
- ROE
- -42.92%
- ROIC
- -38.94%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-79,145,361
- Net Income
- $-94,508,181-10.2%
- EPS
- $-1.81+14.6%
- OCF Growth
- -31.0%
- FCF Growth
- -31.0%
- 52W High
- $34.48
- 52W Low
- $8.31
- 50D MA
- $11.41
- 200D MA
- $20.06
- Beta
- 0.23
- RSI (14)
- 24
- Avg Volume
- 266.91K
No earnings-call transcripts are available for OCS yet.
- Free Float
- 64.8%
- Shares Outstanding
- 57.17M
- Float Shares
- 37.03M
of shares held by institutions
57 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eqt Fund Management S.A R.L. | 6.95M | ▲ 1.05M |
| Abrdn PLC | 2.16M | ▲ 412.86K |
| Millennium Management LLC | 2.04M | ▲ 1.13M |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.51M | ▼ 174.03K |
| Citadel Advisors LLC | 987.20K | ▲ 825.92K |
| Braidwell LP | 834.18K | ▲ 834.18K |
| Perceptive Advisors LLC | 808.83K | ▲ 315.00K |
| Saturn V Capital Management LLC | 684.88K | ▲ 168.12K |
| Sr One Capital Management, LP | 641.02K | 0 |
| Siren, L.L.C. | 625.00K | ▲ 625.00K |
| Ameriprise Financial Inc | 619.92K | ▲ 619.92K |
| Wellington Management Group Llp | 540.06K | ▼ 805.67K |
Held by 8 ETFs
Biggest fund positions in OCS by dollar value.
Our OCS coverage
Recent articles, reports, and earnings notes.
No research on OCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCS report →Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
globenewswire.com · Oct 1
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
globenewswire.com · Oct 1
Oculis Announces Resignation of Lionel Carnot from Board of Directors
globenewswire.com · Sep 30
Oculis Announces Resignation of Lionel Carnot from Board of Directors
globenewswire.com · Sep 30
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
zacks.com · Sep 28
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026
globenewswire.com · Sep 21
Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $39.44
defenseworld.net · Sep 21
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
globenewswire.com · Sep 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.